GalNac is a carbohydrate moiety that binds to asialoglycoprotein receptor 1 (ASGR1) with high affinity and facilitates the uptake of siRNAs into hepatocytes by endocytosis.[20] GalNac‐conjugated siRNAs targeting hepatocyte‐deregulated genes have been approved by the FDA for the treatment of acute hepatic porphyria[21] and have entered phase III trials.[22] HK2 is highly expressed in HCC but barely expressed in healthy hepatocytes, which led us to hypothesize that GalNac‐siHK2 administration is a promising therapeutic strategy for targeting HCC. The gene discussed is ASGR1; the disease is Acute hepatic porphyria.